Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
复制标题
普伐他汀对 HIV 感染男性身体成分和心血管疾病标志物的影响——一项随机、安慰剂对照研究。
DOI：
10.1097/01.aids.0000222072.37749.5a
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Carr,Andrew
中科院分区：
文献类型：
--
作者：
Mallon,PatrickWG;Miller,John;Kovacic,JasonC;Kent-Hughes,Julia;Norris,Richard;Samaras,Katherine;Feneley,MichaelP;Cooper,DavidA;Carr,Andrew
Objectives:To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia.Methods:A randomized, placebo-controlled, 16-week study was carried out on 33 HIV-infected, hypercholesterolaemic men (fasting total cholesterol> 6.5 mmol/L) on PI-containing therapy. Patients commenced dietary assessment and advice at week 0 and were randomized to 12 weeks pravastatin (40 mg each night) or placebo from week 4. The primary endpoint was the time-weighted change (TWAUC) in total cholesterol from week 0. Secondary endpoints included TWAUC cholesterol from week 4 (start of pravastatin), total and regional body fat, fasting lipids, glucose, insulin, and markers of cardiovascular risk.Results:Of 33 men randomized (pravastatin n= 16, mean age 48 years), 31 completed the study. Groups were matched for baseline cholesterol and body composition. Although there was no significant between-group difference in TWAUC cholesterol from week 0 (pravastatin− 0.6±1.0 versus placebo− 0.4±1.0 mmol/L/week; P= 0.8), TWAUC cholesterol from week 4 decreased more in the pravastatin group (− 0.8±1.0 versus− 0.3±0.9 mmol/L/week; P= 0.04). Neither triglycerides nor dietary intake changed. Subcutaneous fat increased significantly with pravastatin (+ 0.72±1.55 versus+ 0.19±0.48 kg change in limb fat, P< 0.04;+ 5.2±8.7 versus− 1.3±13.7 cm 2 change in abdominal subcutaneous fat, P= 0.02). Apart from homocystine, which decreased in the pravastatin group, there were no significant differences in other cardiovascular, lipid or glucose parameters.Conclusions:Despite limited effects on cholesterol, 12 weeks use of pravastatin 40 mg each night in HIV-infected men with hypercholesterolaemia resulted in significant increases in subcutaneous fat.
